AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06544434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy)
Description: MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.
Study NCT06544434 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Multiwave Locked System (MLS) laser (Mphi laser, ASA Srl, Vicenza, Italy)
Description: MLS laser is a class IV NIR laser with two synchronized sources (905 nm with 75 W peak power, pulsed mode; 808 nm with power 1 W, continuous mode). Both laser beams were synchronized, the locked waves work with the range 1-2000 Hz.
Study NCT06544434 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Betahistine Mesylate tablet
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.
Study NCT06544434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betahistine Mesylate tablet
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.
Study NCT06544434 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Betahistine Mesylate tablet
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.
Study NCT05176418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose Nicotine
Description: IV nicotine infused over different delivery rates
Study NCT04842864 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: 23 hours fasting
Study NCT04842864 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: 23 hours fasting
Study NCT06314490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nL-SCN2A-002
Description: Personalized antisense oligonucleotide
Study NCT06138275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: subcutaneous (under the skin) injection
Study NCT06414512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMBITION trial control
Description: Induction therapy for control group participants followed the 2018 WHO cryptococcal guidelines with 7 days of 5-FC 100mg/kg/day and 7 days of IV Amphotericin deoxycholate followed by 1200mg fluconazole/day for 7 days.
Study NCT06414512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucytosine
Description: Participants in the trial will receive 60mg/kg/day of 5-FC in 3 divided doses for 10 days. Single-dose liposomal amphotericin (10mg/kg) is preferred, if available. Amphotericin B 0.7-1.0 mg/kg/day may be used if needed.
Study NCT05342103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high flow oxygenation
Description: All patients will have FiO2 started at 0.4 and titrated to maintain oxygen saturation (SpO2) ≥ 95%.
Study NCT04833101 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: recombinant Ad5 vectored COVID-19 vaccine
Description: This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
Study NCT04833101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant Ad5 vectored COVID-19 vaccine
Description: This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
Study NCT04833101 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RBD-based protein subunit vaccine (ZF2001) against COVID-19
Description: This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.
Study NCT04833101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBD-based protein subunit vaccine (ZF2001) against COVID-19
Description: This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25μg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.
Study NCT05176418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose Nicotine
Description: IV Nicotine infused over different delivery rates
Study NCT05742139 — intervention group
Intervention type: OTHER
Intervention: Non intervention
Description: Non intervention
Study NCT04833101 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: trivalent split influenza vaccine
Description: This vaccine contains 15 μ g H1NI, 15 μ g H3N2 and 15 μ g B-series hemagglutinin, produced by Dalian Aleph Biomedical Co., Ltd.It is a liquid dosage form, 0.5 ml / bottle.
Study NCT00057187 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Contracting, Prompting and Reinforcing
Study NCT05285254 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Certified Child Life Specialist Support
Description: Provides psychosocial care to children and families confronting stressful and painful situations
Study NCT05261503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEP
Description: The Homeostasis-Enrichment-Plasticity (HEP) intervention group will receive 45 minutes of face-to-face environmental enrichment-based intervention one day per week and online home support once a week for 12 weeks.
Study NCT05261503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Phsical Therapy
Description: The Traditional Physical Therapy group will receive a 45-minute intervention, two days a week for 12 weeks.
Study NCT06110741 — intervention group
Intervention type: OTHER
Intervention: Blood and saliva sampling
Description: Collecting blood and saliva sample
Study NCT06110741 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Collecting data on infectious diseases during the study period
Study NCT06317350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS-212-E1
Description: Subjects who are randomized into this group will take GNS-212-E1 from the evening before colonoscopy to the morning of colonoscopy.
Study NCT06317350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNS-212-E2
Description: Subjects who are randomized into this group will take GNS-212-E2 from the evening before colonoscopy to the morning of colonoscopy.
Study NCT06317350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNS-212-ER
Description: Subjects who are randomized into this group will take active control drug (PEG3350) from the evening before colonoscopy to the morning of colonoscopy.
Study NCT04177381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section
Description: 1. Abdominal Incision: Pfannenstiel incision Sharp dissection will be continued through the subcutaneous layer to the fascia.~2. The fascia will be then incised sharply at the midline~3. The transversalis fascia and pre peritoneal fat will be dissected carefully~4. The peritoneum will be then incised.~5. Low Transverse Cesarean Incision. Bladder flap creation effectively moves the bladder away from the planned hysterotomy site~6. Delivery of the Fetus and placenta.~7. Uterine Repair in two layers of continuous 0-or No.1 absorbable suture.
Study NCT04177381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subcutanous sutures
Description: suture closure of subcutaneous tissue with interrupted 2-0 polyglactin 910 (Vicryl).the stitch interval is 1cm
Study NCT04177381 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: subcutanous drain
Description: Inthedraingroup,aclosednonvacuum drain willbeinsertedin thetissueandexitefrom theskinthroughaseparateopeningandstitchto theskin
Study NCT04975828 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: albumin creatinine ratio -EGFR-fundus examination- coronary angiography.
Description: albumin creatinine ratio and EGFR to assess. diabetic nephropathy. fundus examination to assess. diabetic retinopathy. assess of coronary artery disease by coronary angiography. assess diabetic nephropathy by neurologic examination.
Study NCT05394233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed
Description: Bevacizumab: 7.5 mg/kg administered as an intravenous infusion on Day 1 of each 3-week cycle Cisplatin 75 mg/m2 will be administered as an intravenous infusion over 2 hours, every 3 weeks, Pemetrexed, 500 mg/m2, intravenously every 3 weeks, Tislelizumab, 200 mg IV every 3 weeks
Study NCT05833243 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified diaphragmatic training
Description: Modified diaphragmatic strength training prescriptions will be given based on the result of baseline assessment. The intensity is 60% from the maximum respiratory muscle strength from baseline and weekly remeasurement. Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist.
Study NCT05833243 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard diaphragmatic training
Description: standard diaphragmatic strength training prescriptions will be given as daily routine, 3 times a day.~Participants are asked to come for weekly follow-up and commit to do at least 20 sessions of exercise. The training is under supervision of physical medicine and rehabilitation specialist.
Study NCT04913818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BUDPA Program
Description: The overall program includes 12 weekly 1-hour training class. Each session starts with a 10-minute warm-up period using stretching exercise and stationary mobilizing exercise for trunk and limb joints at both upper and lower bodies (e.g. shoulders, elbows, wrists, hips, knees and ankles), and followed by a session of four to six selected partnering exercise, with duration increase gradually from 20 minutes to 40minutes in four weeks' time. The Borg Rate of Perceived Exertion (Borg RPE) will be used to monitor the exercise intensity. The Research assistant will explain the Borg RPE scale to the subjects and instruct them to speed up or slow down their movements. The training session will end with a 10-minute cool down session with walking exercise and stationary trunk and limb mobilizing exercise involving joints of shoulders, elbows, wrists, hips, knees, and ankles.
Study NCT04913818 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm (Usual care)
Description: Active Comparator: Usual Care Activities will be provided by the elderly community center such as dementia or caregiver supporting service. They will be allowed to use the regular service provided such services are not related to physical activity or exercise training
Study NCT04788069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wholemeal bread
Description: 180g wholemeal bread/day + fixed portion at test day
Study NCT04788069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sourdough bread
Description: 180g sourdough bread/day + fixed portion at test day
Study NCT04788069 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bread with sourdough
Description: 180g bread with sourdough/day + fixed portion at test day
Study NCT04173312 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine infusion
Description: Local systemic Infusion of anesthetic
Study NCT04173312 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Local systemic infusion of saline
Study NCT06312982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Enrolled patients will receive tislelizumab 3 times after initiation of radiotherapy.
Study NCT06012864 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PNL
Description: percutaneous extraction of the stones in the kidney
Study NCT04925258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPACE Parenting Program
Description: The program involves a two-arm randomized trial of differing parenting interventions which include: a service as usual (SAU) cohort, in which parents are provided with local and online parenting and family mental health resources; An intervention group called SPACE that includes weekly parenting materials (i.e., two online \~10-minute videos, ten parent-child activities that were developed for the Building Regulation in Dual Generations (BRIDGE) Therapy program (NCT04347707 and NCT04639557) intervention group. Additionally, this group will receive weekly drop-in sessions with a facilitator-led (trained MA-level or higher psychology student or psychologist) interactive parenting group to re-enforce concepts and provide social support.
Study NCT05428904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulation
Description: Virtual reality applications are a type of three-dimensional computer-based simulation that gives a sense of being anywhere and provides various data to the sense organs for this. However, virtual reality applications are a simulation model that creates a sense of reality for the participants and allows mutual communication with a computer-based dynamic environment.
Study NCT04694729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: videoconference-based
Description: Exercises will be done 3 days a week for 6 weeks, with the help of a physiotherapist via video conference.
Study NCT04694729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-based
Description: The exercise video will be sent to the patients and they will do it 3 days a week for 6 weeks. The subjects will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
Study NCT06155084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP518 - Dose Escalation
Description: Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
Study NCT06155084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP518 -Dose Expansion
Description: Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
Study NCT05284019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Concentrate for solution for IV infusion
Study NCT05284019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Solution for SC Injection
Study NCT05284019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin-A
Description: Solution for IM Injection
Study NCT05284019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Solution for SC Injection
Study NCT05284019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Solution for SC Injection
Study NCT04884425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Electromagnetic Frequency Device (Energy5)
Description: A pulsed electromagnetic frequency (PEMF) device which is recommended to be used for 30 minutes a day
Study NCT06324071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sham
Description: Participants in the Control group will receive a daily dose of placebo in a capsule during 90 days.
Study NCT06324071 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marine microalgae Tetraselmis chuii with high Superoxide Dismutase (SOD) activity
Description: Participants in the Experimental group will receive a daily dose of 125 mg of TetraSOD® in a capsule during 90 days.
Study NCT04996199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: oxcarbazepine 150mg BD initial dose , followup will be done at 15days, 6weeks, 10 weeks interval
Study NCT04996199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: carbamazepine 100mg BD initial dose, follow up will be done 2weeks, 6 weeks \& 10weeks
Study NCT04843124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote HA adjustment
Description: The intervention group is offered remote hearing aid adjustment whilst the control group is offered traditional hearing aid adjustment the requires physical appointments at the clinic. Remote hearing aid adjustment is applicable through mobile applications that hearing aid users download to their mobile phones.
Study NCT04843124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional hearing aid
Description: Traditional hearing aid
Study NCT06516055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1B-408
Description: Medication with multiple monoamine activities
Study NCT05407532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group with oral management
Description: The investigators provided information on oral health care plus oral exercises before meals, including salivary glands massage methods.
Study NCT05407532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group with oral care
Description: The investigators taught and monitored patients or caregivers to do oral care after meals and before sleep.
Study NCT05713760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirbanibulin Ointment 1%
Description: Klisyri® ointment is a microtubule inhibitor for topical use and is currently on the market for the treatment of actinic keratosis of the face or scalp. The chemical name of tirbanibulin is N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl) acetamide. Tirbanibulin ointment 1% contains 10 mg tirbanibulin per gram of white to off-white ointment containing mono- and di-glycerides and propylene glycol and is supplied in packets containing 250 mg of tirbanibulin ointment 1%. Each packet includes single-dose packets (2.5 mg tirbanibulin in 250 mg) to be applied to evenly cover up to 25 cm² of the treatment field once daily for 5 consecutive days using 1 single-dose packet per application.
Study NCT06475287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC（Mitoxantrone+Raltitrexed）、anlotinib、TQB2450
Description: The combination therapy of HAIC with TQB2450 and Anlotinib was administered to enrolled patients in no particular order. Patients received routine hepatic artery catheterization via femoral artery puncture, followed by routine hepatic artery catheterization and infusion chemotherapy with 5% sodium bicarbonate 150ml + liposomal mitoxantrone (10mg) for 2-4 hours + Raltitrexed (2mg/m2) for 2-4 hours, every three weeks for at least two cycles. Systemic treatment was given every 21 days, with a fixed dose of 1200mg of TQB2450 injection on the first day of each systemic treatment cycle (1-7 days after HAIC treatment), administered intravenously over 60 minutes initially, followed by 30 minutes if tolerated. Anlotinib was administered orally once daily at a dose of 10mg, with a two-week break every three weeks. Treatment continued until unacceptable toxicity or loss of clinical benefit (as assessed by the investigator based on imaging, biochemical indicators, and patient clinical status).
Study NCT05450445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: myHealthHub
Description: myHealthHub is a multimodal patient engagement platform delivered on bedside terminals to provide hospital inpatients with social connection, meal ordering services, entertainment (TV, etc.), and access to medical care team.
Study NCT05450445 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TV-only
Description: myHealthHub device equipped with the TV-only entertainment option.
Study NCT06547398 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive radiotherapy +/- Margin Reduction
Description: Radiotherapy using adaptive technology to recontour and replan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.
Study NCT06547398 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Image guided radiotherapy
Description: Standard radiation treatment used in the department of radiation oncology for prostate cancer
Study NCT05437822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 2 g of tranexamic acid in 50 mL of saline
Study NCT04778514 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dual Prevention Pill
Description: a single over-encapsulated DPP containing a PrEP tablet and a COC
Study NCT04778514 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PrEP and combined oral contraceptive (COC) as two separate tablets
Description: PrEP tablet and a COC as two separate tablets
Study NCT05635136 — intervention group
Intervention type: OTHER
Intervention: Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy
Description: Dynamic full-field optical coherence tomography analysis of kidney transplant biopsy before conventional histopathological analysis
Study NCT05943314 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL1/+CD33 CAR-T
Description: CLL1/+CD33 CAR T is a type of CAR T cell therapy for patients with treating/relapsed acute myeloid leukemia.
Study NCT06312293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: All techniques used to stimulate the vagal nerve are called vagus nerve stimulation.